The Economist quotes CGD senior health program associate Rachel Nugent on malarial drug-resistance.
From the article:
"But that does not guarantee success, says Rachel Nugent of the Centre for Global Development. As she points out, ACTs are complex and costly to develop and make. The new Brazilian pill will sell for about $2.50 per adult dose. That is cheaper than buying the drugs separately, but much more expensive than the dodgy monotherapies uncovered by the researchers. It is also pricier than Coartem, which Novartis sells for under $1 a dose."
Read the article
